Asia
The companies will harness BridGene’s IMTAC (Isobaric Mass Tagged Affinity Characterization) Chemoproteomics platform to identify targets and small molecule drug candidates.
One of the big drugs investors, analysts and pretty much everyone else in the biopharma industry is keeping an eye on is Biogen and Eisai’s aducanumab for Alzheimer’s disease.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Zenas BioPharma announced it has launched a cross-border biopharmaceutical company based in both China and the U.S.
The investment made to build this end-to-end cell culture biopharmaceutical contract development and manufacturing organization facility clocked in at approximately $2 billion.
Merck and Eisai announced that their combination of Merck’s checkpoint inhibitor Keytruda and Eisai’s Lenvima, a tyrosine kinase inhibitor, significantly improved progression-free survival in advanced endometrial cancer.
The results published in the NEJM state that pegcetacoplan met the study’s primary endpoint for efficacy, demonstrating an advantage over eculizumab with a statistically significant improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16 (p<0.001). An impressive 85% of patients were transfusion free at 16 weeks, in contrast to only 15% of eculizumab-treated patients.
European genetic studies aren’t particularly accurate when applied to Middle East populations, according to new research from the Qatar Foundation.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
PRESS RELEASES